John Lee
2019 - PhaseBio Pharmaceuticals
In 2019, John Lee earned a total compensation of $780.9K as Chief Medical Officer at PhaseBio Pharmaceuticals, a 56% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $176,800 |
|---|---|
| Option Awards | $199,350 |
| Salary | $395,500 |
| Other | $9,205 |
| Total | $780,855 |
Lee received $395.5K in salary, accounting for 51% of the total pay in 2019.
Lee also received $176.8K in non-equity incentive plan, $199.4K in option awards and $9.2K in other compensation.
Rankings
In 2019, John Lee's compensation ranked 10,320th out of 13,971 executives tracked by ExecPay. In other words, Lee earned more than 26.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,320 out of 13,971 | 26th |
Division Manufacturing | 4,177 out of 5,701 | 27th |
Major group Chemicals And Allied Products | 1,604 out of 2,200 | 27th |
Industry group Drugs | 1,373 out of 1,886 | 27th |
Industry Pharmaceutical Preparations | 1,022 out of 1,398 | 27th |
Source: SEC filing on April 24, 2020.
Lee's colleagues
We found two more compensation records of executives who worked with John Lee at PhaseBio Pharmaceuticals in 2019.
News
Marathon Patent Group CFO Hugh Gallagher receives $4.8M in 2022
June 23, 2023
Decibel Therapeutics CEO Laurence Reid's 2022 pay jumps 54% to $1.2M
April 28, 2023
PhaseBio Pharmaceuticals CEO Jonathan Mow's 2021 pay slips 13% to $1.5M
April 22, 2022
PhaseBio Pharmaceuticals CEO Jonathan Mow's 2019 pay jumps 102% to $1.2M
April 24, 2020
PhaseBio Pharmaceuticals CEO Jonathan Mow's 2018 pay jumps 37% to $596K
April 5, 2019